Deutsche Bank AG Takes $1.32 Million Position in Enovis Corporation $ENOV

Key Points

• Deutsche Bank acquired 63,979 Enovis shares worth approximately $1.32 million, joining other institutional investors. Hedge funds and other institutions now own 98.45% of the company.
• Enovis exceeded quarterly expectations, reporting adjusted EPS of $0.90 versus the $0.85 consensus estimate and revenue of $582.78 million, up 3.2% year over year.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $41.29 versus the stock’s recent price near $24.91.

Deutsche Bank AG acquired a new position in Enovis Corporation (NYSE:ENOV - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 63,979 shares of the company's stock, valued at approximately $1,324,000. Deutsche Bank AG owned about 0.11% of Enovis at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. California State Teachers Retirement System lifted its stake in Enovis by 1.2% in the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company's stock worth $1,622,000 after purchasing an additional 621 shares in the last quarter. MGO One Seven LLC lifted its position in Enovis by 9.4% during the fourth quarter. MGO One Seven LLC now owns 7,581 shares of the company's stock worth $202,000 after buying an additional 650 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock worth $40,000 after buying an additional 707 shares during the last quarter. Empowered Funds LLC grew its holdings in Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company's stock valued at $249,000 after buying an additional 749 shares in the last quarter. Finally, Arax Advisory Partners acquired a new stake in shares of Enovis in the 4th quarter worth $29,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Enovis Stock Up 0.3%

Enovis stock opened at $24.91 on Friday. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of -1.29 and a beta of 1.34. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. Enovis Corporation has a fifty-two week low of $19.14 and a fifty-two week high of $34.28. The stock's fifty day moving average is $25.60 and its two-hundred day moving average is $24.25.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The business had revenue of $582.78 million for the quarter, compared to analysts' expectations of $581.84 million. During the same quarter last year, the firm earned $0.79 earnings per share. The business's revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts predict that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Analyst Ratings Changes

ENOV has been the topic of several recent analyst reports. Evercore set a $32.00 price objective on shares of Enovis in a report on Monday, July 6th. BMO Capital Markets restated an "outperform" rating and set a $30.00 price target on shares of Enovis in a research report on Friday, August 7th. Canaccord Genuity Group dropped their price objective on Enovis from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Monday, August 17th. Wells Fargo & Company decreased their target price on Enovis from $40.00 to $39.00 and set an "overweight" rating on the stock in a research note on Friday, August 7th. Finally, Weiss Ratings upgraded shares of Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, July 21st. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Enovis presently has a consensus rating of "Moderate Buy" and an average target price of $41.29.

Insiders Place Their Bets

In related news, insider Oliver Engert acquired 1,200 shares of the firm's stock in a transaction on Thursday, June 11th. The stock was bought at an average cost of $21.62 per share, with a total value of $25,944.00. Following the acquisition, the insider directly owned 51,840 shares in the company, valued at approximately $1,120,780.80. The trade was a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders purchased 4,200 shares of company stock worth $92,084. 2.90% of the stock is owned by company insiders.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.